New treatments for HIV-1 in patients with tuberculosis in South Africa
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa
This study is looking at how well certain HIV medications work for kids who also have tuberculosis, to make sure they are safe and effective when taken together.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Centre/aids Programme/res/south Africa NIH-funded |
| Lab location | 1 site (Durban, SOUTH AFRICA) |
| Project ID | NIH-10898925 on NIH RePORTER |
What this research studies
This research focuses on the effectiveness of second-generation integrase strand transfer inhibitors (InSTIs) like dolutegravir and bictegravir for treating HIV-1 in patients who are also being treated for tuberculosis (TB). Given the high rates of HIV and TB co-infection in South Africa, the study aims to determine the appropriate dosing and safety of these medications, especially in young children who are on rifampicin-based TB treatment. The research will involve assessing how these drugs interact with TB medications and their overall effectiveness in this unique patient population.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals of all ages, particularly those co-infected with HIV and TB who are undergoing rifampicin-based treatment.
Not a fit: Patients who are not co-infected with HIV and TB or those not receiving rifampicin-based treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with both HIV and TB, enhancing their health outcomes.
How similar studies have performed: Previous research has shown promising results with integrase strand transfer inhibitors in HIV treatment, but this specific approach for co-infected patients is novel.
Where this research is happening
Durban, SOUTH AFRICA
- Centre/aids Programme/res/south Africa — Durban, South Africa (Active)
Researchers
- Principal investigator: Naidoo, Anushka — Centre/aids Programme/res/south Africa
- Study coordinator: Naidoo, Anushka
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.